Systemwide Enhancements Deliver Exceptional Configurability, Performance and Efficiency
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is proud to announce the latest release of iMedNet™ eClinical, its innovative, cloud-based technology platform. iMedNet provides an extremely intuitive, flexible and affordable software-as-a-service (SaaS) solution – ideal for clinical trial sponsors and CROs wishing to quickly and efficiently build studies themselves.
"This iMedNet release delivers significant new and enhanced functionality throughout the system, encompassing our easy-to-use forms designer and randomization modules, as well as our casebook manager and robust reporting toolsets," remarked M. Clareece West, Chief Operating Officer of MedNet Solutions. "At MedNet, we're dedicated to continually refining our eClinical technologies to ensure we always deliver fully compliant and validated best-in-class solutions. Our most recent iMedNet release is tangible proof of that promise to our customers."
"We're incredibly excited about the latest iMedNet release," stated John M. (Rob) Robertson, President and CEO of MedNet Solutions. "It takes our iMedNet platform to the next level in terms of convenience, speed and control, not only for our customers, but for everyone involved in the clinical research initiative. And we're not stopping there; we're working on more exciting new functionality that will be rolled out early this coming summer. Stay tuned."
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.